# A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

> **NCT05394012** · PHASE1 · UNKNOWN · sponsor: **Walvax Biotechnology Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** RQ3013
- **BIOLOGICAL:** Comirnaty

## Key facts

- **NCT ID:** NCT05394012
- **Lead sponsor:** Walvax Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12
- **Primary completion:** 2023-02
- **Final completion:** 2023-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05394012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05394012, "A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05394012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*